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Immunologic Markers of Progression to Acquired
Immunodeficiency Syndrome are Time-Dependent and Illness-
Specific
Alexander Kramer,1 Robert J. Biggar,2 Hartmut Hampl,3 Robert M. Friedman,4
Dietmar Fuchs,5 Helmut Wachter,5 and James J. Goedert2
Since prevalent cohorts may be biased by the duration of human immunodeficiency
virus (HIV) infection (onset bias), it is useful to assess the potential predictive value of
markers in incident cohorts of HIV-positive subjects for whom the date of seroconversion
is known or can reliably be estimated. Of 131 homosexual men with HIV-1 seroconver-
sion from New York City and Washington, DC, who were evaluated annually beginning
in 1982,60 developed acquired immunodeficiency syndrome (AIDS) by the end of 1989.
The prognostic significance of immunologic markers (proportion of CD4+ T-lymphocytes,
neopterin, /?2-microglobulin, serum interferon, and anti-p24 antibody) and of a virologic
marker (HIV p24 antigen) was determined using measurements made at defined time
intervals after the known or estimated date of HIV seroconversion. When measurements
made 3 years after seroconversion were used, all markers except anti-p24 antibody
were found to be significant estimators of AIDS risk in univariate analyses. In multivariate
Cox regression modeling, the maximum information was obtained by including neop-
terin, interferon, and the CD4+ T-lymphocyte proportion. The predictive value of markers
after HIV seroconversion could change considerably from one interval to another.
Elevated levels of /32-microglobulin and neopterin significantly predicted the development
of Kaposi's sarcoma. These two markers were highly correlated (r = 0.74). The authors
conclude that immunologic markers can be important for an HIV staging system for
estimating prognosis and facilitating early therapeutic intervention in HIV-positive pa-
tients. Am J Epidemiol 1992;136:71-80.
beta 2-microglobulin; HIV antibodies; HIV antigens; HIV-1; interferons; proportional
hazards models; pteridines; T4 lymphocytes
The risk of developing acquired immu-
nodeficiency syndrome (AIDS) among per-
sons infected by the human immunodefi-
ciency virus (HIV) can be estimated by a
variety of immunologic and virologic mark-
ers, such as the CD4+ T-lymphocyte count,
urinary or serum neopterin, /32-microglobu-
lin, interferon, soluble interleukin-2 recep-
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tors, presence of HIV p24 antigen, and an-
tibodies to p24 or gpl20 (1-7). We have
recently shown that the levels of some im-
munologic markers may significantly pre-
dict the risk of developing AIDS as early as
5 years before diagnosis (8). To assess the
absolute risk of the development of AIDS in
an HIV-1 seropositive individual, we pro-
spectively evaluated immunologic and virol-
ogic markers of AIDS in HIV-positive ho-
mosexual men using actuarial methods. As
studies of prevalently seropositive subjects
are potentially biased because the duration
of HIV-infection is unknown (onset bias)
(9), markers were analyzed in relation to the
known or estimated time of HIV serocon-
version.
MATERIALS AND METHODS
Subjects and study design
Of 131 HIV-1 seropositive homosexual
men evaluated approximately annually
since 1982 (1), 60 had developed AIDS by
the end of 1989. A seroconversion date,
defined as the midpoint between the last
negative and first positive sample, was avail-
able for 47 of the 131 infected men. For the
84 men already infected at the onset of the
study, seroconversion dates were estimated
using the method of backcalculation to de-
velop regional norms. The average date of
seroconversion for men in New York who
were seropositive in 1982 was probably June
1980; for those in Washington, DC, it was
probably June 1981 (10). To check the reli-
ability of this approach, the annual and cu-
mulative AIDS incidence rates using these
imputed seroconversion dates were exam-
ined and found to be very similar to those
of subjects in the same cohort with midpoint
seroconversion dates (8).
Laboratory assays
HIV-1 antibodies were determined by a
commercial enzyme-linked immunosorbent
assay (Electronucleonics Inc., Columbia,
MD), and reactive samples were confirmed
by Western blot analysis (Biotech Inc.,
Rockville, MD). The relative proportion of
CD4+ T-lymphocytes was measured in
lymphocytes that had been frozen and
thawed using a fluorescence-activated cell
sorter and OKT4 monoclonal antibodies
(Ortho Diagnostics Co., Raritan, NJ). Serum
neoptenn was retrospectively measured by
radioimmunoassay (Neopterin RIAcid,
Henning-Berlin, Berlin, Germany), and /32-
microglobulin was measured in serum using
double-antibody radioimmunoassay (fo-
micro RIA, Pharmacia, Uppsala, Sweden).
Serum interferon was measured in 96-well
microtiter plates with the use of human FS-
4 fibroblasts; a challenge was performed with
the encephalomyocarditis virus, as described
elsewhere (11). A level of >4 international
units (IU) was considered positive. HIV-1
p24 antigen was determined with a com-
mercial enzyme-linked immunosorbent as-
say (Abbott Laboratories, North Chicago,
IL). For confirmation of antigen positivity,
an HIV-1 p24 neutralization test was per-
formed. Anti-p24 antibodies were also
determined using an enzyme-linked immu-
nosorbent assay (Abbott Laboratories). For
the determination of anti-p24 antibody ti-
ters, an anti-p24 quantitation assay (Abbott
Laboratories) was used in accordance with
the manufacturer's specifications. Poten-
tially prognostic laboratory markers were
measured sequentially at defined time inter-
vals after HIV seroconversion. These inter-
vals were defined in years (±6 months) from
the date of seroconversion.
Statistical analysis
The method of Kaplan and Meier (12)
was used to estimate AIDS-free survival. For
this analysis, the markers were divided into
approximate terciles, or analyzed in a di-
chotomous fashion with the categories ab-
sent or present. For comparison of Kaplan-
Meier curves, log-rank statistics were calcu-
lated. Cox's proportional hazards model (13)
was used to assess the predictive value of the
covariates singly and in combination. Gen-
erally, the covariates were treated as contin-
uous variables—CD4+ T-lymphocyte pro-
portion, neopterin, /32-microglobulin, and
anti-p24 antibodies—or as categorical vari-
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ables—HIV p24 antigen (absent/present)
and interferon (absent/present). Interferon
was coded as follows: code 0 (absent), <4
IU; codes 1-5 (present)—code 1, 4 to <8
IU; code 2, 8 to <12 IU; code 3, 12 to <20
IU; code 4, 20 to <50 IU; and code 5, >50
IU. A stepwise procedure was performed to
determine the relative importance of the
covariates in predicting the progression to
AIDS. Since the proportion of CD4+ T-
lymphocytes has been well established as a
predictive marker of AIDS, all bivariate and
multivariate models included this variable.
Comparison and choice of models were
based on their 2 log-likelihood estimates. For
example, first, all possible univariate models
were analyzed; second, all bivariate combi-
nations including the proportion of CD4+
T-lymphocytes at any rate were analyzed;
then, third, the best bivariate model accord-
ing to the 2 log-likelihood estimates was used
as the basis for multivariate models with
three combinations of markers. More elab-
orate models were not used, because the full
model containing all possible variables did
not improve the 2 log-likelihood estimate
substantially above the level of three vari-
ables. These analyses were performed pro-
spectively to estimate the relative hazard of
AIDS following measurements taken at de-
fined time intervals after HIV seroconver-
sion. The time intervals 3 years after sero-
conversion, 4 years after seroconversion, 5
years after seroconversion, and after the level
of CD4+ lymphocytes had dropped below
500/ml were chosen because there were suf-
ficient complete sets of marker measure-
ments for these intervals. Spearman rank-
order correlation was used for calculation of
correlation coefficients between markers.
RESULTS
AIDS-free survival
Complete sets of marker data were avail-
able for 81 of the 131 HIV-seropositive ho-
mosexual men; 36 of these 81 men devel-
oped AIDS during the observation period.
Only data for the 81 subjects with complete
sets of marker data were used in the Kaplan-
Meier analysis. As illustrated in Kaplan-
Meier plots (figures 1-6), AIDS-free survival
3 years after HIV seroconversion differed at
various levels for immunologic and virologic
markers. This was significant for the CD4+
T-lymphocyte proportion, neopterin, /32-
microglobulin, interferon, and HIV p24 an-
tigen, but not for anti-p24 antibody (p =
0.06). For example, at 1,525 days (4.18
years), the AIDS-free survival in subjects
with a CD4+ T-lymphocyte proportion of
<25 percent was zero; it was approximately
60 percent in subjects whose CD4+ T-
lymphocyte proportion was between 25 and
35 percent, and 70 percent for those whose
CD4+ T-lymphocyte proportion was >35
percent. At this same time interval, 77 per-
cent of the subjects with neopterin levels of
<10 nmol/liter were AIDS-free, compared
with 56 percent of those with neopterin lev-
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FIGURE 1. Kaplan-Meier plots of the proportion of
subjects without AIDS by approximate tercile of the
CD4+ T-lymphocyte proportion 3 years after serocon-
version. (Key: n, number of HIV-seropositive subjects
without AIDS at time 0; vertical tick marks, subjects
without AIDS who were censored; the p value for the
difference in disease-free survival was derived from the
log-rank test).
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FIGURE 2. Kaplan-Meier plots of the proportion of
subjects without AIDS by approximate tercile of serum
neopterin 3 years after seroconversion. (Key: n, number
of HIV-seropositive subjects without AIDS at time 0;
vertical tick marks, subjects without AIDS who were
censored; the p value for the difference in disease-free
survival was derived from the log-rank test).
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FIGURE 3. Kaplan-Meier plots of the proportion of
subjects without AIDS by approximate tercile of &>-
microglobulin 3 years after seroconversion. (Key: n,
number of HIV-seropositive subjects without AIDS at
time 0; vertical tick marks, subjects without AIDS who
were censored; the p value for the difference in disease-
free survival was derived from the log-rank test).
els of 10-15 nmol/liter and only 26 percent
of those with levels of >15 nmol/liter. With
respect to serum interferon, AIDS-free sur-
vival was 0 after 2,154 days (5.9 years) when
interferon was present, compared with about
53 percent when interferon had been absent.
The interval of 3 years after seroconversion
was chosen because the marker measure-
ments were most complete at this interval.
Proportional hazards models for AIDS
Table 1 shows the results from univariate,
bivariate, and multivariate analyses using
proportional hazards models to assess the
predictive value of the markers singly and in
combination. Again, all markers except anti-
p24 antibody proved to be single significant
AIDS predictors. Bivariate and multivariate
combinations are only displayed for models
that include the proportion of CD4+ T-
lymphocytes, because the predictive poten-
tial of this marker is beyond doubt. As illus-
trated by the 2 log-likelihood estimates, the
model incorporating neopterin, interferon,
and the CD4+ T-lymphocyte proportion (2
log-likelihood = -239.65) was the best pre-
dictive model, resulting in the following haz-
ard function equation:
X(0 = X0(0 exp(0.0900 neopterin
+ 0.4462 interferon - 0.0221 CD4%),
where CD4% equals the relative proportion
of CD4+ T-lymphocytes. Compared with
this model, the full model with all markers
included did not add significant informa-
tion: (difference in 2 log-likelihood: -238.45
+ 239.65 = 1.2, p> 0.2).
In addition, we evaluated the prognostic
potential of the markers as time-dependent
variables. In other words, did the prognostic
value of a given marker vary with measure-
ments of this marker at different times in
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FIGURE 4. Kaplan-Meier plots of the proportion of
subjects without AIDS by the presence or absence of
interferon 3 years after seroconversion. (Key: n, number
of HIV-seropositive subjects without AIDS at time 0;
vertical tick marks, subjects without AIDS who were
censored; the p value for the difference in disease-free
survival was derived from the log-rank test).
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FIGURE 5. Kaplan-Meier plots of the proportion of
subjects without AIDS by the presence or absence of
HIV p24 antigen 3 years after seroconversion. (Key: n,
number of HIV-seropositive subjects without AIDS at
time 0; vertical tick marks, subjects without AIDS who
were censored; the p value for the difference in disease-
free survival was derived from the log-rank test).
the course of HIV disease? Therefore, we
analyzed proportional hazards models for
AIDS using as starting points measurements
made at different times after HIV serocon-
version and after CD4+ T-lymphocyte
counts had dropped below 500/ml. Table 2
displays beta coefficients and standard errors
for the model incorporating the CD4+ T-
lymphocyte proportion, neopterin, and in-
terferon at these various other intervals. One
sees that the predictive value of markers can
change considerably from one time interval
to another. Prognostic models at different
times after HIV seroconversion could, there-
fore, contain different combinations of
markers (data not shown).
Prognostic markers for the development
of Kaposi's sarcoma
In order to be specific for a given category
of AIDS illness, we analyzed prognostic
markers in the subgroup of subjects whose
only initial manifestation of AIDS was
Kaposi's sarcoma as compared with markers
in HIV-positive controls who did not de-
velop AIDS during the study period. Since
the data were sparse (11 cases), this analysis
was performed in a univariate fashion only
(table 3). Despite the small number of sub-
jects, neopterin and /32-microglobulin were
both found to be significant predictors of
Kaposi's sarcoma (p = 0.0009 and p =
0.044, respectively). Since opportunistic in-
fections were the most frequent initial man-
ifestation of AIDS (43 cases), the predictive
markers for this illness category were very
similar to those presented above for the en-
tire group of AIDS patients.
Correlations between markers
Table 4 shows the correlations among the
six markers from all measurements taken 3
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FIGURE 6. Kaplan-Meier plots of the proportion of
subjects without AIDS by approximate tercile of anti-
HIV p24 antibody 3 years after seroconversion. (Key:
n, number of HIV-seropositive subjects without AIDS
at time 0; vertical tick marks, subjects without AIDS
who were censored; the p value for the difference in
disease-free survival was derived from the log-rank
test).
years after HIV seroconversion (Spearman
rank-order correlation coefficients). In ad-
dition to anti-p24 antibody and p24 antigen
(r = -0.59, p = 0.0001), ft-microglobulin
and neopterin were also very highly corre-
lated (r = 0.74, p = 0.0001).
DISCUSSION
We analyzed the potential of immuno-
logic and virologic markers to predict AIDS
in relation to HIV seroconversion, with
measurements taken at different time inter-
vals after seroconversion and before the on-
set of AIDS. When measurements made 3
years after HIV seroconversion were used,
various immunologic markers (the propor-
tion of CD4+ T-lymphocytes, neopterin, /32-
microglobulin, and interferon) and p24 an-
tigen were significant predictors of AIDS for
the next 6 years, that is, up to the ninth year
after HIV infection (figures 1-6). A propor-
tional hazards model incorporating neop-
terin, interferon and the CD4+ T-
lymphocyte proportion had the best predic-
tive value for progression of HIV-positive
homosexual men to AIDS (table 1).
It was interesting that the prognostic value
of markers could vary considerably during
HIV disease (table 2). A marker may thus
be a good predictor shortly after seroconver-
sion but fail to estimate the subsequent risk
of AIDS accurately when measured late in
the course of HIV infection, or vice versa.
Since the variation of estimates may partly
be due to the sparse number of subjects,
further studies with larger numbers are
needed to obtain more precise estimates of
the subsequent risk of AIDS for different
intervals, and to characterize the exact pat-
tern over time. Nonetheless, our findings
clearly indicate that the predictive value of
the markers is time-dependent. The follow-
ing hazard function equation takes this time-
dependence into account:
X(0 = X0(0
+ . . . +
It should also be noted that longer time since
HIV seroconversion was itself predictive of
AIDS (data not shown), even in the full
model.
We are aware that the date of HIV sero-
conversion of an HIV-seropositive individ-
ual is usually not known in the clinical set-
ting. Therefore, one may conclude that the
time-dependence with respect to the predic-
tive value of AIDS progression markers is
only of theoretical interest and of no prac-
tical importance. However, an approximate
seroconversion date can be estimated for
many persons with prevalent infections
based on the history of specific exposures
(e.g., rare anal intercourse, contact with a
prostitute, or condom failure) or symptoms
compatible with the HIV seroconversion
syndrome that may occur in one quarter of
all incident HIV infections.
In addition, one must be specific about
the AIDS illness category: Markers of im-
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TABLE 1. Analyses of potential markers of progression to AIDS* using proportional hazards modelsf with
measurements made 3 years after HIV* seroconversion
Proportional hazards model SE§ p value 2 Log-likelihood
Null model
Univariate models
CD4+ T-lymphocytes (%)
Neopterin (nmol/liter)
j32-Microglobulin (mg/liter)
Interferon (codes 0-5)
HIV p24 antigen (0-1)
Anti-p24 antibody (mg/liter)
Bivariate models
CD4+ T-lymphocytes (%)
Neopterin (nmol/liter)
CD4+ T-lymphocytes (%)
02-Microglobulin (mg/liter)
CD4+ T-lymphocytes (%)
Interferon (codes 0-5)
CD4+ T-lymphocytes (%)
HIV p24 antigen (0-1)
CD4+ T-lymphocytes (%)
Anti-p24 antibody (mg/liter)
Multivariate models
CD4+ T-lymphocytes (%)
Neopterin (nmol/liter)
/32-Microglobulin (mg/liter)
CD4+ T-lymphocytes (%)
Neopterin (nmol/liter)
Interferon (codes 0-5)
CD4+ T-lymphocytes (%)
Neopterin (nmol/liter)
HIV p24 antigen (0-1)
CD4+ T-lymphocytes (%)
Neopterin (nmol/liter)
Anti-p24 antibody (mg/liter)
Full model
CD4+ T-lymphocytes (%)
Neopterin (nmol/liter)
/32-Microglobulin (mg/liter)
Interferon (codes 0-5)
HIV p24 antigen (0-1)
Anti-p24 antibody (mg/liter)
-277.16
0.0519
0.1145
0.7225
0.8172
0.8672
0.00002
0.0268
0.1185
0.0304
0.6259
0.0313
0.7214
0.0399
0.5077
0.0487
0.00002
0.0250
0.1053
0.1584
0.0221
0.0900
0.4462
0.0261
0.1173
0.0512
0.0258
0.1157
0.00001
0.0214
0.0843
0.0615
0.4295
0.0674
0.00001
0.0195
0.0240
0.1687
0.1453
0.3384
0.00002
0.0137
0.0278
0.0185
0.1827
0.0184
0.1536
0.0210
0.3757
0.0194
0.00002
0.0139
0.0317
0.2368
0.0142
0.0314
0.1902
0.0146
0.0293
0.4019
0.0135
0.0274
0.00002
0.0150
0.0365
0.2595
0.1989
0.4213
0.00002
0.008
0.0001
0.0001
0.0001
0.01
0.39
0.05
0.0001
0.099
0.0006
0.089
0.0001
0.057
0.18
0.012
0.42
0.072
0.0009
0.50
0.12
0.004
0.019
0.073
0.0001
0.90
0.055
0.0001
0.49
0.15
0.021
0.81
0.031
0.87
0.50
-268.23
-250.01
-262.11
-253.86
-270.85
-274.31
-244.25
-258.49
-250.28
-266.42
-266.30
-243.83
-239.65
-244.24
-243.01
-238.45
• AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus.
f Note that models were built hierarchically upon the CD4* T-lymphocyte proportion because the predictive value of this marker
is well established.
% The regression coefficients refer to the units in parentheses next to the variables. For example, for the univariate model "CD4*
T-lymphocytes," the coefficient represents a negative change of 0.0519 related to a unit percentage change in CD4+ T-lymphocytes.
For "Interferon (codes 0-5)," the coefficient is related to a change of one code, e.g., from 2 to 3, etc.
§ SE, standard error of the regression coefficient.
mune system stimulation, neopterin and ft-
microglobulin, were significant predictors
for Kaposi's sarcoma in our univariate anal-
yses (table 3). This has already been sug-
gested by a descriptive analysis of our cohort
(14) and by another study (15). However,
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TABLE 2. Results of the proportional hazards model incorporating the CD4+ T-lymphocyte proportion,
neopterin, and interferon at different times of HIVt disease
Time of HIV disease SE§ p value
3 years after seroconversion (n = 81)
CD4+ T-lymphocytes (%)
Neopterin (nmol/liter)
Interferon (codes 0-5)
4 years after seroconversion (n = 65)
CD4+ T-lymphocytes (%)
Neopterin (nmol/liter)
Interferon (codes 0-5)
5 years after seroconversion (n = 49)
CD4+ T-lymphocytes (%)
Neopterin (nmol/liter)
Interferon (codes 0-5)
<500 CD4+ T-lymphocytes/jd (n = 76)
CD4+ T-lymphocytes (%)
Neopterin (nmol/liter)
Interferon (codes 0-5)
0.0221
0.0900
0.4462
0.0593*
0.0539
0.2457
0.0594
0.0800
0.5178
0.0920**
0.0487
0.0597***
0.0142
0.0314
0.1902
0.0235
0.0397
0.1857
0.0337
0.0313
0.1914
0.0244
0.0249
0.1332
0.12
0.004
0.019
0.01
0.17
0.19
0.078
0.01
0.007
0.0002
0.05
0.65
• p = 0.09, " p = 0.01, • * *p = 0.05, if compared with the regression coefficient of the marker for the interval 3 years after
seroconversion.
t HIV, human immunodeficiency virus.
X The regression coefficients refer to the units in parentheses next to the variables.
§ SE, standard error of the regression coefficient.
since the number of subjects was sparse,
other markers, such as the CD4+ T-
lymphocyte proportion, may also become
significant predictors of Kaposi's sarcoma
with a larger number of subjects.
The results reported here are in agreement
with our earlier findings that significant
changes in the CD4+ T-lymphocyte propor-
tion, neopterin, and ft-microglobulin oc-
curred within 1 -2 years after seroconversion
in subjects who developed AIDS during the
study period (8). They are also in agreement
with our report from early in the HIV epi-
demic that serum interferon activity pre-
dicted AIDS in subjects with hemophilia
(16) and with reports from other investiga-
tors who found elevated neopterin and /32-
microglobulin levels early in HIV infection
(17-19). Recently, we were able to demon-
strate that the risk of AIDS can be predicted
with immunologic markers as early as even
1 year after HIV seroconversion (20), which
supports the observation that events occur-
ring soon after or around seroconversion
influence the progression to AIDS (21). Un-
derstanding the pathogenesis of immunolog-
ically severe HIV seroconversions may pro-
vide therapeutic opportunities to reduce the
risk of AIDS further.
In our analysis, immunologic markers
were superior to HIV p24 antigen in their
potential to predict progression to AIDS.
Neopterin is a compound of low molecular
weight derived from dihydroneopterintri-
phosphate, an intermediate in the de novo
synthesis of tetrahydrobiopterin from guan-
osine triphosphate. Neopterin was found to
be present in high concentrations in super-
natants of mixed cultures of mononuclear
cells from human peripheral blood and of
monocytes and macrophages stimulated by
7-interferon (22). /32-Microglobulin is a pro-
tein of low molecular weight that is present
on the surface of all nucleated cells as the
constant subunit of class I histocompatibility
antigens (23). Most of the interferon activity
that we detected was a-interferon, although
complete formal characterization has not
been done (7). Mononuclear cells, including
monocytes, natural killer cells, and B-
lymphocytes, produce a-interferon in re-
sponse to infections with viruses, other in-
tracellular organisms, and other inducers
(24). Although the specific inducer or indue-
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TABLE 3. Univariate analyses of markers in HIV*-seropositive subjects whose only initial manifestation of
AIDS* was Kaposi's sarcoma
Null model
Univariate models
CD4+ T-lymphocytes (%)
Neopterin (nmol/liter)
fo-Microglobulin (mg/liter)
Interferon (codes 0-5)
HIV p24 antigen (0-1)
Anti-p24 antibody (mg/liter)
0.0105
0.2456
1.2035
0.0204
-0.6197
SE*
0.0404
0.0738
0.5967
0.4973
1.0698
p value
0.8
0.0009
0.044
0.97
0.56
(no convergence)
2 Log-
likelihood
-64.70
-64.63
-53.55
-60.72
-64.70
-64.31
• HIV, human immunodeficiency virus; AIDS, acquired immunodeficiency syndrome,
t The regression coefficients refer to the units in parentheses next to the variables.
X SE, standard error of the regression coefficient.
TABLE 4. Spearman rank order correlations of markers of progression to AIDS* based on measurements
made 3 years after HIV* seroconversion
CD4%f Neopterin fo-Microglobulin Interferon p24Antigen
Neopterin
ft-Microglobulin
Interferon
p24 Antigen
Anti-p24 antibody
-0.48
-0.48
-0.35
-0.45
0.28
0.74
0.42
0.41
-0.31
0.38
0.33
-0.28
0.29
-0.23 -0.59
• AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus,
t Proportion of CD4* T-lymphocytes
ers of neopterin, /?2-microglobulin, and in-
terferon have not been defined, these serum
proteins are products of immunostimula-
tion. Their roles in elucidating the pathogen-
esis of AIDS have not yet been precisely
defined.
The Centers for Disease Control classifi-
cation system provides a clinical basis for
case definition (25) but does not characterize
the degree of illness, pathobiology, or prog-
nosis. On the other hand, the "Walter Reed
staging classification for HTLV-III/LAV in-
fection" (26) characterizes the progressive
nature of the pathobiology and is prognostic.
However, the Walter-Reed system requires
not only a physical examination and T-cell
testing but also delayed hypersensitivity test-
ing with a battery of skin test antigens that
must be read by trained personnel 48 hours
after application. Our data suggest that a
combination of immunologic markers, in-
cluding the CD4+ T-lymphocyte proportion,
neopterin or /32-microglobulin, and serum
interferon might provide a convenient alter-
native method of assessing prognosis in
HIV-positive individuals. These serological
tests are relatively inexpensive by Western
medical standards, with costs in the range of
a standard HIV antibody test. Since neop-
terin and ft-microglobulin are very highly
correlated (table 4), it may be sufficient to
determine only one of these two markers.
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